Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Zhejiang UniversityActive in the last 2 years

Qida Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9092-7808; OpenAlex author ID A5067811638. Sources: OpenAlex.

Their work

Papers
8 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 8

  1. Antigen Spreading via Localized Administration Enhances Adoptive TCR-T Cell Therapy in Pancreatic Cancer. Last author DOI 10.1002/advs.76135↗
  2. STING-activating pyroptotic nanoparticles for in situ pancreatic cancer vaccination and immunotherapy. Co-author DOI 10.1016/j.scib.2025.04.015↗
  3. Correction: Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy. First author DOI 10.1186/s12951-024-03033-y↗
  4. In Situ Formed ROS-Responsive Hydrogel with STING Agonist and Gemcitabine to Intensify Immunotherapy against Pancreatic Ductal Adenocarcinoma. First author DOI 10.1002/adhm.202203264↗
  5. An Ionic Liquid Ablation Agent for Local Ablation and Immune Activation in Pancreatic Cancer. Co-author DOI 10.1002/advs.202206756↗
  6. Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy. First author DOI 10.1186/s12951-022-01282-3↗
  7. Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis. Co-author DOI 10.1016/j.canlet.2014.09.048↗
  8. Hypoxia-inducible factor 1α expression and its clinical significance in pancreatic cancer: a meta-analysis. Co-author DOI 10.1016/j.pan.2014.06.008↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shiyi Shao · 6 shared papers, 2022–2026 · strength 1.30
  2. Tingbo Liang · 4 shared papers, 2014–2025 · strength 0.73
  3. Tingbo Liang · 3 shared papers, 2014–2026 · strength 0.47
  4. Meng Wang · 2 shared papers, 2022–2025 · strength 0.41
  5. Junming Huang · 2 shared papers, 2023 · strength 0.39
  6. Junming Huang · 1 shared paper, 2026 · strength 0.27
  7. Xiazhen Yu · 1 shared paper, 2025 · strength 0.23
  8. Meng Wang · 1 shared paper, 2023 · strength 0.19
  9. Tingbo Liang · 1 shared paper, 2023 · strength 0.19
  10. Qi Zhang · 2 shared papers, 2014 · strength 0.09
  11. Xueli Bai · 2 shared papers, 2014 · strength 0.09
  12. Long‐Yun Ye · 1 shared paper, 2014 · strength 0.05
  13. Xiao Zhi · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.